enGene price target raised to $33 from $30 at Oppenheimer

Oppenheimer raised the firm’s price target on enGene (ENGN) to $33 from $30 and keeps an Outperform rating on the shares. The firm believes the reveal from the pivotal LEGEND trial in high-risk NMIBC is not only impressive in its own right – highlighted by detalimogene’s 62% 6-month complete response rate – but also addresses the market’s skepticism following last September’s initial showing, which preceded changes that brought the trial’s design closer to current standards for this indication.